- Home
- WATT vs TSBX Comparison
WATT vs TSBX Comparison
Compare WATT & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- TSBX
- Stock Information
- Founded
- WATT 2012
- TSBX 2015
- Country
- WATT United States
- TSBX United States
- Employees
- WATT N/A
- TSBX N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- TSBX
- Sector
- WATT Technology
- TSBX
- Exchange
- WATT Nasdaq
- TSBX Nasdaq
- Market Cap
- WATT 9.1M
- TSBX 8.4M
- IPO Year
- WATT 2014
- TSBX 2023
- Fundamental
- Price
- WATT $0.31
- TSBX $0.38
- Analyst Decision
- WATT Strong Buy
- TSBX Buy
- Analyst Count
- WATT 2
- TSBX 3
- Target Price
- WATT $2.25
- TSBX $4.75
- AVG Volume (30 Days)
- WATT 603.9K
- TSBX 128.8K
- Earning Date
- WATT 05-13-2025
- TSBX 05-12-2025
- Dividend Yield
- WATT N/A
- TSBX N/A
- EPS Growth
- WATT N/A
- TSBX N/A
- EPS
- WATT N/A
- TSBX N/A
- Revenue
- WATT $768,000.00
- TSBX N/A
- Revenue This Year
- WATT $1,028.91
- TSBX N/A
- Revenue Next Year
- WATT N/A
- TSBX N/A
- P/E Ratio
- WATT N/A
- TSBX N/A
- Revenue Growth
- WATT 62.02
- TSBX N/A
- 52 Week Low
- WATT $0.26
- TSBX $0.34
- 52 Week High
- WATT $2.70
- TSBX $3.88
- Technical
- Relative Strength Index (RSI)
- WATT 45.03
- TSBX 44.54
- Support Level
- WATT $0.26
- TSBX $0.37
- Resistance Level
- WATT $0.31
- TSBX $0.42
- Average True Range (ATR)
- WATT 0.03
- TSBX 0.04
- MACD
- WATT 0.00
- TSBX 0.00
- Stochastic Oscillator
- WATT 44.55
- TSBX 37.25
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.